Summary

5.79 0.34(6.24%)09/27/2024
Vicarious Surgical Inc. (RBOT)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
6.24-3.19-5.089.31-79.70-84.960.00-97.88


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close5.79
Open5.50
High5.79
Low5.37
Volume9,206
Change0.34
Change %6.24
Avg Volume (20 Days)811,746
Volume/Avg Volume (20 Days) Ratio0.01
52 Week Range0.20 - 3.56
Price vs 52 Week High62.64%
Price vs 52 Week Low2,795.00%
Range-1.49
Gap Up/Down-0.05
Fundamentals
Market Capitalization (Mln)32
EBIDTA0
PE Ratio0.0000
PEG Ratio0.0000
WallStreet Target Price15.25
Book Value0.0810
Earnings Per Share-5.1610
EPS Estimate Current Quarter-0.0500
EPS Estimate Next Quarter-0.0600
EPS Estimate Current Year-0.6000
EPS Estimate Next Year-0.5500
Diluted EPS (TTM)-5.1610
Revenues
Profit Marging0.0000
Operating Marging (TTM)0.0000
Return on asset (TTM)0.0000
Return on equity (TTM)0.0000
Revenue TTM0
Revenue per share TTM0.0000
Quarterly Revenue Growth (YOY)0.0000
Quarterly Earnings Growth (YOY)0.0000
Gross Profit (TTM)0
Dividends
Dividend Share0.0000
Dividend Yield
Valuations
Trailing PE0.0000
Forward PE0.0000
Price Sales (TTM)0.0000
Price Book (MRQ)0.0000
Revenue Enterprise Value 0.0000
EBITDA Enterprise Value0.0000
Shares
Shares Outstanding98,832,400
Shares Float35,120,508
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.00
Insider (%)43.21
Institutions (%)30.10


08/12 19:40 EST - seekingalpha.com
Vicarious Surgical Inc (RBOT) Q2 2024 Earnings Call Transcript
Vicarious Surgical Inc (NYSE:RBOT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - IR Bill Kelly - CFO & Treasurer Adam Sachs - Co-Founder, CEO & Director Conference Call Participants Eric Anderson - TD Cowen Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2024 Second Quarter Earnings Call.
08/08 12:11 EST - zacks.com
Vicarious Surgical (RBOT) Partners LSU Health New Orleans
Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.
06/10 16:15 EST - businesswire.com
Vicarious Surgical Announces Reverse Stock Split
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will effect a 1-for-30 reverse stock split of the Company's issued and outstanding Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share. The reverse stock split was approved by Vicarious S.
04/29 20:54 EST - investorplace.com
RBOT Stock Earnings: Vicarious Surgical Meets EPS for Q1 2024
Vicarious Surgical (NYSE: RBOT ) just reported results for the first quarter of 2024. Vicarious Surgical reported earnings per share of -9 cents.
04/29 20:16 EST - seekingalpha.com
Vicarious Surgical Inc. (RBOT) Q1 2024 Earnings Call Transcript
Vicarious Surgical Inc. (NYSE:RBOT ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - Head, Investor Relations Adam Sachs - Co-Founder and CEO Bill Kelly - Chief Financial Officer Randy Clark - President Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - TD Cowen Operator Hello. And welcome to Vicarious Surgical's 2024 First Quarter Earnings Call.
04/29 16:05 EST - businesswire.com
Vicarious Surgical Reports First Quarter 2024 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, April 29, 2024. “I'm proud to report a productive start to 2024 as we advance our mission to improve lives by t.
04/08 16:30 EST - businesswire.com
Vicarious Surgical to Report First Quarter 2024 Financial Results on April 29, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in l.
03/04 17:32 EST - seekingalpha.com
Vicarious Surgical Inc. (RBOT) Q4 2023 Earnings Call Transcript
Vicarious Surgical Inc. (NYSE:RBOT ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - IR Adam Sachs - CEO William Kelly - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Good afternoon, and welcome to Vicarious Surgical's Fourth Quarter 2023 Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.
03/04 16:10 EST - businesswire.com
Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, March 4, 2024. “We made meaningful progress transitioning our Beta 2.
02/20 08:30 EST - businesswire.com
Vicarious Surgical to Participate in TD Cowen's 44th Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will participate in the TD Cowen 44th Annual Healthcare Conference. Management is scheduled to present on Tuesday, March 5, 2024 at 2:10 p.m. ET. A live webcast of the presentation will be accessible to th.
02/12 16:30 EST - businesswire.com
Vicarious Surgical to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Monday, March 4, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investor.
01/29 08:30 EST - businesswire.com
Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0.
11/15 08:30 EST - businesswire.com
Vicarious Surgical to Present at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will present at the Piper Sandler 35th Annual Healthcare Conference. Management is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 9:00 am ET. Interested parties can access a.
11/13 20:05 EST - seekingalpha.com
Vicarious Surgical Inc. (RBOT) Q3 2023 Earnings Call Transcript
Vicarious Surgical Inc. (NYSE:RBOT ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - Investor Relations Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - TD Cohen Caitlin Cronin - Canaccord Genuity Operator Good afternoon, and welcome to Vicarious Surgical's Third Quarter 2023 Earnings Conference Call. My name is Kate, and I'll be your operator for today's call.
11/13 16:05 EST - businesswire.com
Vicarious Surgical Reports Third Quarter 2023 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, November 13, 2023. “The third quarter brought several successes for our business,.
10/26 09:00 EST - businesswire.com
Vicarious Surgical to Report Third Quarter 2023 Financial Results on November 13, 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the third quarter ended September 30, 2023, after the market closes on November 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in l.
09/22 17:00 EST - businesswire.com
Vicarious Surgical Receives Continued Listing Standard Notice From NYSE
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that on September 20, 2023, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average clo.
09/14 12:01 EST - zacks.com
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
Vicarious Surgical's (RBOT) partnership with Intermountain Health is likely to help the company gain access to Intermountain Health's extensive network.
09/07 16:30 EST - businesswire.com
Vicarious Surgical to Present at the Gilmartin Group Emerging Growth Company Showcase
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will present at the Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to participate in a fireside chat on Thursday, September 21, 2023, at 10:00 am ET. Inte.
08/24 17:42 EST - seekingalpha.com
Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization
Vicarious Surgical is a surgical robotics company developing a next-generation surgical robot with human-like dexterity. The company has a large addressable market of over 45 million abdominal procedures worth $150 billion, but its survival is uncertain due to low cash reserves and high burn. I am personally staying on the sidelines as I believe the risk / reward is better if/when RBOT reaches commercialization with a superior product than currently awaiting regulatory approval.